HEPA Archives - Page 10 of 11

Developments

Hepion to present CRV431 clinical and scientific updates at HEP DART 2019 meeting

Hepion Pharmaceuticals (NASDAQ:HEPA) is slated to present two posters at the HEP DART 2019, frontiers in drug development for hepatology, including viral hepatitis, NASH and co-infections meeting. The presentations...

December 9, 2019

Developments

Hepion’s Drs. Foster, Mayo, Ure and Trepanier appointed adjunct professors at UofA

Hepion Pharmaceuticals’ (NASDAQ:HEPA) Drs. Robert Foster, CEO; Daren Ure, CSO; Daniel Trepanier, SVP drug development; and Patrick Mayo, SVP clinical pharmacology have been appointed adjunct professors by the University...

December 3, 2019

Markets

Brookline starts Hepion Pharma at buy; PT $12

Brookline Capital Markets launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $12 price target. The stock closed at $3.39 on Nov. 21. Hepion is developing CRV431, a novel pleiotropic...

November 22, 2019

Developments

Hepion CRV431 prevents cirrhosis in severe liver disease model

Hepion Pharmaceuticals’ (NASDAQ:HEPA) lead drug candidate, CRV431, prevented the development of cirrhosis in a highly aggressive, preclinical model of liver disease. In the study, rats were administered...

November 20, 2019

Developments

Hepion to present on CRV431’s anti-fibrotic activity at the Liver Meeting 2019

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CSO, Dr. Daren Ure, will present preclinical data on CRV431 at The Liver Meeting 2019. Dr. Ure’s presentation will address CRV431’s ability to decrease liver fibrosis in a carbon...

November 7, 2019

Developments

Hepion CRV431 reduces fibrosis in new model of NASH

Hepion Pharmaceuticals (NASDAQ:HEPA) reported preclinical findings where CRV431, a novel cyclophilin inhibitor, significantly decreased the extent of liver fibrosis in a Western diet (WD) animal model of NASH. The WD...

November 7, 2019

Markets

Roth starts Hepion Pharma at buy; PT $9

Roth Capital Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $9 price target. The stock closed at $2.95 on Nov. 6. “Hepion brings a laser focus on liver disease, combined with...

November 7, 2019

Developments

Hepion to present CRV431’s potential in liver fibrosis at NASH summit

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CSO, Dr. Daren Ure, will discuss the potential of the company’s lead candidate, CRV431, as a treatment for non-alcoholic steatohepatitis (NASH) at the third annual NASH summit. Dr...

October 23, 2019

Developments

JPET publishes Hepion data highlighting CRV431’s potential to treat chronic liver diseases

Hepion Pharmaceuticals (NASDAQ:HEPA) CRV431 data from experimental models of fibrosis and non-alcoholic steatohepatitis (NASH) have been published in the peer-reviewed Journal of Pharmacology and Experimental...

October 16, 2019

Executive Moves

Hepion appoints renowned liver disease expert, Dr. Stephen Harrison, as consultant medical director

Stephen Harrison Hepion Pharmaceuticals (NASDAQ:HEPA) appointed world-renowned Dr. Stephen Harrison as consultant medical director. Dr. Harrison is a peer-reviewer for more than 20 medical journals. He is...

October 10, 2019

Tag - HEPA

Hepion to present CRV431 clinical and scientific updates at HEP DART 2019 meeting

Hepion’s Drs. Foster, Mayo, Ure and Trepanier appointed adjunct professors at UofA

Brookline starts Hepion Pharma at buy; PT $12

Hepion CRV431 prevents cirrhosis in severe liver disease model

Hepion to present on CRV431’s anti-fibrotic activity at the Liver Meeting 2019

Hepion CRV431 reduces fibrosis in new model of NASH

Roth starts Hepion Pharma at buy; PT $9

Hepion to present CRV431’s potential in liver fibrosis at NASH summit

JPET publishes Hepion data highlighting CRV431’s potential to treat chronic liver diseases

Hepion appoints renowned liver disease expert, Dr. Stephen Harrison, as consultant medical director

General

More